AU2015231713B2 - Methods for reducing cardiovascular risk - Google Patents

Methods for reducing cardiovascular risk Download PDF

Info

Publication number
AU2015231713B2
AU2015231713B2 AU2015231713A AU2015231713A AU2015231713B2 AU 2015231713 B2 AU2015231713 B2 AU 2015231713B2 AU 2015231713 A AU2015231713 A AU 2015231713A AU 2015231713 A AU2015231713 A AU 2015231713A AU 2015231713 B2 AU2015231713 B2 AU 2015231713B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015231713A
Other languages
English (en)
Other versions
AU2015231713A1 (en
Inventor
Laurence BESSAC
Corinne Hanotin
Robert C. Pordy
William J. Sasiela
Gregory G. Schwartz
Philippe Gabriel Steg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of AU2015231713A1 publication Critical patent/AU2015231713A1/en
Application granted granted Critical
Publication of AU2015231713B2 publication Critical patent/AU2015231713B2/en
Priority to AU2021201118A priority Critical patent/AU2021201118A1/en
Priority to AU2024205254A priority patent/AU2024205254A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2015231713A 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk Active AU2015231713B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021201118A AU2021201118A1 (en) 2014-03-17 2021-02-19 Methods for reducing cardiovascular risk
AU2024205254A AU2024205254A1 (en) 2014-03-17 2024-07-31 Methods for reducing cardiovascular risk

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201461954094P 2014-03-17 2014-03-17
US61/954,094 2014-03-17
US201462025400P 2014-07-16 2014-07-16
US62/025,400 2014-07-16
US201462043182P 2014-08-28 2014-08-28
US62/043,182 2014-08-28
EP15305293 2015-02-26
EP15305293.1 2015-02-26
PCT/US2015/020564 WO2015142668A1 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021201118A Division AU2021201118A1 (en) 2014-03-17 2021-02-19 Methods for reducing cardiovascular risk

Publications (2)

Publication Number Publication Date
AU2015231713A1 AU2015231713A1 (en) 2016-10-20
AU2015231713B2 true AU2015231713B2 (en) 2020-11-19

Family

ID=52648962

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2015231713A Active AU2015231713B2 (en) 2014-03-17 2015-03-13 Methods for reducing cardiovascular risk
AU2021201118A Abandoned AU2021201118A1 (en) 2014-03-17 2021-02-19 Methods for reducing cardiovascular risk
AU2024205254A Abandoned AU2024205254A1 (en) 2014-03-17 2024-07-31 Methods for reducing cardiovascular risk

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021201118A Abandoned AU2021201118A1 (en) 2014-03-17 2021-02-19 Methods for reducing cardiovascular risk
AU2024205254A Abandoned AU2024205254A1 (en) 2014-03-17 2024-07-31 Methods for reducing cardiovascular risk

Country Status (14)

Country Link
US (2) US20150284473A1 (https=)
EP (2) EP4403213A3 (https=)
JP (3) JP2017509624A (https=)
KR (3) KR20250006995A (https=)
CN (3) CN106794244A (https=)
AU (3) AU2015231713B2 (https=)
CA (1) CA2942549A1 (https=)
EA (1) EA039310B1 (https=)
ES (1) ES2978990T3 (https=)
HU (1) HUE066839T2 (https=)
IL (1) IL304491A (https=)
MX (1) MX380767B (https=)
PL (1) PL3119810T3 (https=)
WO (1) WO2015142668A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
PL3395836T3 (pl) 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW202021614A (zh) 2013-06-07 2020-06-16 法商賽諾菲生物技術公司 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
MX2016006226A (es) 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
AU2015289874A1 (en) * 2014-07-14 2017-02-02 Amgen Inc. Crystalline antibody formulations
PL3169353T3 (pl) 2014-07-16 2020-06-01 Sanofi Biotechnology SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
RU2723018C2 (ru) * 2014-07-16 2020-06-08 Санофи Байотекнолоджи Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
EP3197492A1 (en) 2014-09-23 2017-08-02 Pfizer Inc Treatment with anti-pcsk9 antibodies
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
US10329620B2 (en) * 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
BR112019020148A2 (pt) 2017-04-13 2020-05-05 Cadila Healthcare Limited peptídeo
CA3092936A1 (en) * 2018-03-06 2019-09-12 Sanofi Biotechnology Use of pcsk9 inhibitor for reducing cardiovascular risk
JP7513533B2 (ja) * 2018-07-02 2024-07-09 アブセントラ，エルエルシー リポタンパク質ａの形成を減少させるための組成物及び方法、ならびに大動脈弁硬化症及び大動脈弁狭窄症の治療
CN112912071A (zh) * 2018-08-17 2021-06-04 阿玛林制药爱尔兰有限公司 降低接受他汀类药物治疗的受试者对外周动脉血运重建的需求的方法
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
SG11202107614PA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof
JP7692411B2 (ja) * 2019-11-07 2025-06-13 メディミューン，エルエルシー 心血管疾患の治療用の内皮リパーゼ抗体
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
BR112022009587A2 (pt) * 2019-11-18 2022-08-02 Ad Pharmaceuticals Co Ltd Anticorpo anti-pcsk9 e uso do mesmo
MX2022012752A (es) * 2020-04-15 2023-01-16 Voyager Therapeutics Inc Compuestos de union a tau.
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
CN114848849B (zh) * 2022-04-25 2023-11-17 南方科技大学 Pcsk9蛋白抑制剂在治疗心血管疾病中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PL3395836T3 (pl) * 2011-01-28 2021-12-13 Sanofi Biotechnology Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077854A1 (en) * 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. High affinity human antibodies to pcsk9

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Anonymous, "NCT01507831 on 2013_06_27: ClinicalTrials.gov Archive", (2013-06-27), URL: https://clinicaltrials.gov/archive/NCT01507831/2013_06_27, (2015-05-19) *
Anonymous, "NCT01663402 on 2014_03_11: ClinicalTrials.gov Archive", (2014-03-11), URL: https://clinicaltrials.gov/archive/NCT01663402/2014_03_11, (2015-05-19) *
EVAN A. STEIN ET AL, CURRENT ATHEROSCLEROSIS REPORTS, US, (2013-02-01), vol. 15, no. 3, pages 1 - 14 *
JAMES M. MCKENNEY ET AL, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, (2012-06-01), vol. 59, no. 25, pages 2344 - 2353 *
SCHWARTZ GREGORY G ET AL, AMERICAN HEART JOURNAL, (2014-11), vol. 168, no. 5, pages 682 - 689 *

Also Published As

Publication number Publication date
EP3119810A1 (en) 2017-01-25
MX2016011975A (es) 2016-12-05
CN114642661A (zh) 2022-06-21
HUE066839T2 (hu) 2024-09-28
JP2017509624A (ja) 2017-04-06
US20220144969A1 (en) 2022-05-12
US20150284473A1 (en) 2015-10-08
KR20220157516A (ko) 2022-11-29
AU2024205254A1 (en) 2024-10-03
EP4403213A2 (en) 2024-07-24
JP2024147744A (ja) 2024-10-16
JP2022141868A (ja) 2022-09-29
KR20160132459A (ko) 2016-11-18
CA2942549A1 (en) 2015-09-24
ES2978990T3 (es) 2024-09-23
EA039310B1 (ru) 2022-01-12
KR20250006995A (ko) 2025-01-13
WO2015142668A1 (en) 2015-09-24
EA201691847A1 (ru) 2017-01-30
AU2015231713A1 (en) 2016-10-20
EP4403213A3 (en) 2024-10-23
AU2021201118A1 (en) 2021-03-11
CN114558129A (zh) 2022-05-31
MX380767B (es) 2025-03-12
EP3119810C0 (en) 2024-02-28
EP3119810B1 (en) 2024-02-28
PL3119810T3 (pl) 2024-07-15
CN106794244A (zh) 2017-05-31
IL304491A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
US20220144969A1 (en) Methods for reducing cardiovascular risk
US20250059300A1 (en) METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH) WITH AN ANTI-PCSK9 ANTIBODY
US20200255544A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
US20150231236A1 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
TW201536315A (zh) 治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症之方法
JP2020143156A (ja) 心血管リスクを低減させる方法
HK40114248A (en) Methods for reducing cardiovascular risk
HK1232890A1 (en) Methods for reducing cardiovascular risk
HK1232890B (en) Methods for reducing cardiovascular risk
HK1236135A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1236135B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
EA041556B1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией подвергающихся аферезу липопротеинов

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)